Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022
April 27 2022 - 7:50AM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology, and life sciences industries, today
announced that it will issue financial results for the first
quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time
(12:30 Central European Time).
The Company will host a conference call to discuss the financial
results at 8:30 a.m. Eastern Time (14:30 Central European Time) on
Tuesday, May 10, 2022. Management will refer to a slide
presentation during the call, which will be made available on the
day of the call. To view the slide presentation, please visit the
“Financial Results” page, under the Financial Information tab of
the Company's Investor Relations section of its website.
To participate on the call please dial:
United States: +1 646 664 1960 United Kingdom:
+44 020 3936 2999 Canada: +1 613 699 6539 Italy: +39 06 9450 1060
All other locations: +44 20 3936 2999
Access Code: 156733
Preregistration: Listeners are encouraged to preregister
for the call via the following link:
https://www.incommglobalevents.com/registration/client/10540/stevanato-earnings-call/
whereupon you will be provided with a unique dial-in number and
access code.
For Participants that do not preregister: A live
broadcast of the conference call will also be available online at
the following link: http://www.incommuk.com/customers/online
(access code: 156733).
Replay: An online archive of the broadcast will be
available at the website shortly after the live call and will be
available through Tuesday, May 24, 2022. The recording will be
accessible via the following link:
https://www.incommglobalevents.com/replay/7741/stevanato-earnings-call/
(access code 998900).
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries.
Stevanato Group delivers an integrated, end-to-end portfolio of
products, processes and services that address customer needs across
the entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients.
For more information, please visit www.stevanatogroup.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005568/en/
Investor Relations
Lisa Miles lisa.miles@stevanatogroup.com
Media
Stevanato Group media@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024